Axsome Therapeutics Inc (STU:19X)
€ 81.28 -1.42 (-1.74%) Market Cap: 3.94 Bil Enterprise Value: 3.83 Bil PE Ratio: 0 PB Ratio: 40.50 GF Score: 36/100

Q1 2019 Axsome Therapeutics Inc Earnings Call Transcript

May 09, 2019 / 12:00PM GMT
Release Date Price: €17.37 (+0.40%)
Operator

Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics' conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.

I would now like to turn the conference over to your host, Mark Jacobson, Senior Vice President of Operations at Axsome Therapeutics. Please go ahead.

Mark Jacobson
Axsome Therapeutics, Inc. - SVP, Operations

Thank you, operator. Good morning and thank you all for joining us on today's conference call. This morning, our press release providing details of the Company's financial results for the first quarter 2019, recent clinical and regulatory achievements, and upcoming milestones crossed the wire a short time ago and is available on our website at axsome.com.

We will begin this call with prepared remarks by Dr. Herriot Tabuteau, Chief Executive Officer; Dr. Cedric O'Gorman, Senior Vice President of Clinical Development and Medical Affairs; and Nick Pizzie, Chief Financial Officer. We will then open the line for questions from analysts. Questions will be taken in the order

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot